Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women.

Introduction: The demand for effective and safe treatments of genitourinary syndrome (GSM) in post-menopausal women (PMW) is growing. Published data on the efficacy and safety of ospemifene (OSP) prompt an updated literature review to enlighten possible improvements in the GSM treatment.

Area Covered: We searched articles published in English from 2010 to 2023 through Medline (PubMed) and Embase databases with Boolean terms: OSP, PMW, GSM, endometrium, breast cancer, cardiometabolic syndrome, bone metabolism, adherence to treatment, and patient satisfaction.

Vulvovaginal atrophy in women with and without a history of breast cancer: Baseline data from the PatiEnt satisfactiON studY (PEONY) in Italy.

Objectives: To assess clinical characteristics of postmenopausal women with moderate/severe vulvovaginal atrophy, as well as its impact on sexual function, well-being, and quality of life, and to provide an overview of most used treatments.

Study Design: Ongoing longitudinal, observational study conducted in 17 Italian gynecology centers, involving women already treated or initiating a local vaginal estrogen therapy or ospemifene. We report baseline data for women with and without a history of breast cancer.

Fractional CO laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects.

The composition of vaginal microbiome in menopause and cancer survivor women changes dramatically leading to genitourinary syndrome of menopause (GSM) in up to 70% of patients. Recent reports suggest that laser therapy may be valuable as a not hormonal therapeutic modality. The aim of the present study was to evaluate the effects of fractional CO laser treatment on the vaginal secretory pathway of a large panel of immune mediators, usually implicated in tissue remodeling and inflammation, and on microbiome composition in postmenopausal breast cancer survivors.

Erratum to: Long-term reliability of fractioned CO laser as a treatment for vulvovaginal atrophy (VVA) symptoms.

In original publication, the Fig. 1 was incorrect. The correct figure has been given below.

Long-term reliability of fractioned CO laser as a treatment for vulvovaginal atrophy (VVA) symptoms.

Purpose: The aim of this study was to evaluate long-term effects of the fractional CO laser for the treatment of vulvovaginal atrophy (VVA) symptoms.

Methods: Women presenting with VVA symptoms and meeting inclusion criterion were enrolled to fractioned CO laser therapy. Patient's satisfaction was measured on five-point Likert scale at 4 weeks and 6, 12, 18, 24 months after treatment by interview and clinical examination for vaginal livability.

Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors.

Purpose: The aim of this study was to evaluate the efficacy of fractional CO2 laser therapy in breast cancer survivors as a therapeutic method for vulvovaginal atrophy (VVA) dyspareunia.

Methods: 50 patients (mean age 53.3 years) underwent fractional microablative CO2 laser treatment for dyspareunia in oncological menopause (mean time of menopause 6.

Management options of breast cancer related osteoporosis.

Breast cancer therapy after surgery has been improved in recent years. Adjuvant therapies like aromatase inhibitors are being extensively used among breast cancer survivors. This leaded to cancer related and iatrogenic osteoporosis.

Acupuncture and traditional Chinese medicine for hot flushes in menopause: a randomized trial.

Objective: To evaluate the effect of acupuncture on hot flushes and other menopause-related symptoms used in an integrated system, including such therapeutic techniques as diet therapy and Tuina self-massage.

Design: Randomized trial.

Setting: Outpatient center.

Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.

Owing to the improved effectiveness of the treatment protocols for oncological disease, in the last few years we have seen an increase in the number of women in iatrogenic menopause secondary to integrated oncological treatments or surgical, pharmacological or radiological therapies. Particularly if it is premature, menopause in these subjects, who are already strongly debilitated by the primary pathology, may have heavy physical and psychic repercussions on the quality of life.Particular attention must be paid to the prevention and treatment of osteoporosis, which is linked both to premature cessation of the reproductive capacity and to the treatments for the oncological disease, which may represent an additional risk for the development of premature, severe osteoporosis.